IP Library Granted Patent US 10,443,035
Granted Patent B2
US 10,443,035 · App. 15/729,258 · Granted Oct 15, 2019

Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

Inventors: Stephen C. Alley (Bothell, WA); Scott C. Jeffrey (Bothell, WA); Django Sussman (Bothell, WA); Dennis R. Benjamin (Bothell, WA); Brian Toki (Bothell, WA); Patrick J. Burke (Bothell, WA)
Assignee: Seattle Genetics, Inc.
C12N5/0037C07H13/04C07K16/00C07K2317/72C07K2317/732
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,443,035
App. No.
15/729,258
Granted
Oct 15, 2019
Kind
B2
Abstract

The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

Claims (18)

1. A fucose analog having one of the following formulae (I) or (II):

or a biologically acceptable salt or solvate thereof, wherein

each of formula (I) or (II) can be the alpha or beta anomer or the corresponding aldose form;

each of R 1 -R 4 is independently selected from the group consisting of —OH, —OC(O)H, —OC(O)C 1 -C 10 alkyl, —OC(O)aryl, —OC(O)heterocycle, —OC(O)C 1 -C 10 alkylene aryl, —OC(O)C 1 -C 10 alkylene heterocycle, —OCH 2 OC(O) alkyl, —OCH 2 OC(O)O alkyl, —OCH 2 OC(O) aryl, —OCH 2 OC(O)O aryl, —OC(O)CH 2 O(CH 2 CH 2 O) n CH 3 , and —OC(O)CH 2 CH 2 O(CH 2 CH 2 O) n CH 3 , wherein each n is an integer independently selected from 0-5; and

R 5 is selected from the group consisting of —C≡CH, —C≡CCH 3 , —CH 2 C≡CH, —C(O)OCH 3 , —CH(OAc)CH 3 , —CN, —CH 2 CN, —CH 2 Br, —CH 2 Cl, —CH 2 I, and -methoxiran;

provided that R 5 is not —C≡CH when any of R 1 -R 4 is —OH or —OAc, and the fucose analog is other than a compound selected from the group consisting of:

the alpha or beta anomer thereof, and the corresponding aldose form thereof.

2. The fucose analog of claim 1 , wherein each of R 1 -R 4 is independently selected from the group consisting of —OH and —OC(O)C 1 -C 10 alkyl.

3. The fucose analog of claim 1 , wherein each of R 1 -R 4 is independently selected from the group consisting of —OH and —OAc.

4. The fucose analog of claim 1 , wherein R 5 is selected from the group consisting of —C≡CH and —C≡CCH 3 .

5. The fucose analog of claim 1 , wherein R 5 is —C(O)OCH 3 .

6. The fucose analog of claim 1 , wherein R 5 is selected from the group consisting of —CN and —CH 2 CN.

7. The fucose analog of claim 1 , wherein R 5 is —CH 2 CN.

8. The fucose analog of claim 1 , wherein R 5 is —CH 2 Br, —CH 2 Cl, or —CH 2 I.

9. The fucose analog of claim 1 , wherein R 5 is —CH 2 Br or —CH 2 I.

10. The fucose analog of claim 1 , wherein R 5 is —CH 2 Br.

11. The fucose analog of claim 1 , wherein R 5 is methoxiran.

12. The fucose analog of claim 1 , wherein R 5 is —CH(OAc)CH 3 .

Assignments (1)
CHANGE OF NAME Recorded Feb 18, 2021
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 055334/0754 →